Synovial sarcoma X breakpoint 2 protein (SSX2)

Synovial sarcoma X breakpoint 2 protein (SSX2) is a member of the cancer-testis antigen (CTA) family, characterized by its highly restricted expression in the testis of healthy adults and its aberrant re-expression in various malignancies [UniProt: Q16385]. Biologically, SSX2 functions as a transcriptional repressor that interacts with polycomb group proteins and the BAF (SWI/SNF) complex to modulate chromatin architecture and gene silencing [PMID: 15188361, PMID: 10360851]. In synovial sarcoma, a characteristic t(X;18)(p11;q11) chromosomal translocation results in the SS18-SSX2 fusion protein, which acts as a primary oncogenic driver by disrupting epigenetic regulation [PMID: 24631835]. Beyond its role in fusion-driven sarcomas, SSX2 is highly immunogenic and is expressed in melanoma, prostate cancer, and multiple myeloma, making it an ideal target for immunotherapy [PMID: 10601213]. Current therapeutic development focuses on T-cell receptor (TCR) engineered T-cell therapies, such as GSK3903371, and peptide-based vaccines designed to induce a targeted cytotoxic T-lymphocyte response against SSX2-positive tumors [NCT03041311]. These strategies typically require patient selection based on both tumor SSX2 expression and specific HLA types, most commonly HLA-A*02:01, to ensure effective antigen recognition.

Other names

Cancer/testis antigen 5.2CT5.2HOM-MEL-40Protein SSX2SSX2ASSX2B

T-cell receptor (TCR) mediated cytotoxic cell killing of SSX2-expressing tumor cells; Immunological priming and activation of the adaptive immune system via peptide vaccination [PMID: 21149403, NCT03041311].